• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward to Acquire Maaguzi for $11M, Profits Down in Q2

Phase Forward to Acquire Maaguzi for $11M, Profits Down in Q2

July 28, 2009
CenterWatch Staff

Within days of announcing the pending acquisition of Covance’s interactive voice and web response business, eClinical company Phase Forward announced Monday it has purchased technology company Maaguzi for $11 million cash.

With operations in Indianapolis, Ind., and Morrisville, N.C., Maaguzi provides electronic patient reported outcomes (ePRO) services to the pharmaceutical industry. The acquisition of Maaguzi's lead technology, OutcomeLogix, facilitates Phase Forward’s entry into the ePRO and observational studies market. Maaguzi’s chief operating officer Scott Dixon will join Phase Forward as vice president of its newly formed Outcome Logix Group.

“We believe our recent acquisitions are critical steps to ensuring that Phase Forward maintains and extends its current leadership position,” Phase Forward chairman and CEO Bob Weiler told investors on a conference call last night.

The Waltham, Mass.-based company also reported financial results for the second quarter of 2009, reflecting a $1.5-million decrease in net income. GAAP net income for the quarter was $2.2 million, or $0.05 per diluted share, compared with $3.7 million, or $0.08 per diluted share in 2008. Q2 revenues were up 29% to $52.5 million, compared with revenues of $40.9 million in the second quarter of 2008.

Phase Forward's shares were down 9% to $14.27 in afternoon trading Tuesday.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing